Navigation Links
Kiwa Bio-Tech Products Group Discusses Cooperative Research With the University of Waterloo, Canada

BEIJING and CLAREMONT, Calif., Feb. 5 /Xinhua-PRNewswire-FirstCall/ -- Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT) reports on a meeting between Kiwa CEO and Board Chairman, Mr. Wei Li, and Dr. Xiao-Dong Huang from the Department of Biology, the University of Waterloo, Canada to discuss the possibility of collaboration in research and development (R&D) of plant growth promoting rhizobacteria (PGPR) base bio-products and biotechnology for agriculture production and environment protection.

Dr. Xiao-Dong Huang works at the University of Waterloo (UW) as the Director of International Collaboration Education Program of China 2+2 and Research Associate Professor of the Department of Biology. The biotechnology research group composed of Dr. Huang, Dr. Glick and Dr. Greenberg has developed several bio-products and bio-techniques that have been successfully applied to the agricultural and environmental industry.

During the meeting, Dr. Huang agreed with Mr. Wei, Li that great potential exits for collaboration between the UW group and Kiwa on research and development of PGPR based bio-products and biotechnology. Dr. Huang presented information about their commercial applications in agriculture and environment, including successful applications in petroleum and salt contaminated soil remediation. The results from commercial field applications have shown their distinct positive effects on petroleum degradation in oil fields and vegetation recovery from salt impacted soils in Western Canada. In addition, Dr, Huang has also identified that PGPR based technology can be used in commercial operations in agricultural production, including:
-- Increasing crop tolerance and yield in saline soils,

-- Reducing and degrading agro-chemical residual and pollution, and

-- Increasing effectiveness of chemical fertilizers,

-- Reducing chemical fertilizers and pesticide use, and

-- Increasing yield and improve crop quality.

After discussion, Dr. Huang looked forward to meeting with Pro. Qi Wang, Director of Kiwa-CAU R&D Center and to establishing collaboration relations with Kiwa Corp.

Mr. Wei Li, Chairman of the Board and CEO of the Company, stated, "This was a successful meeting, both parties agreed and are willing to cooperate. Based on the established firm strategic cooperative relations, on agricultural industry penetration and development, with China Agricultural Ministry, China Green Food Association and other institutions, together with the technological support from China Agriculture University, we expect to build a cooperative relation with Dr. Huang's research team to develop and introduce some new bio- tech products with significant commercial value meeting the market requirements in China."


The Company develops, manufactures, distributes and markets innovative, cost-effective, and environmentally safe bio-technological products for agricultural and natural resources and environmental conservation. The Company has acquired the rights to manufacture and market AF-01 Anti-viral Aerosol Agent for use in preventing (blocking) bird-flu disease in Chinese and international markets. The Company has excellent relations with government authorities in China and has developed several innovative, high margin products, while continuing to grow through internal and external product development. The Company's products are designed to enhance the quality of human life by increasing the value, quality and productivity of crops and decreasing the negative environmental impact of chemicals and other wastes. For more information about the Company, please review documents filed with the SEC ( or visit the Company's website at

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described by the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.


Kiwa Bio-Tech Products Group Corporation

Yvonne Wang

(626) 715-5855

Robert Schechter

Equity Communications


SOURCE Kiwa Bio-Tech Products Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kiwa Bio-Tech Products Group Discusses Cooperative Efforts With Canadian Agricultural Ministry and Canadian Company
2. Kiwa Bio-Tech Ships 114 Tons of Bio-Fertilizer in Fourth Quarter of 2007
3. Kiwa Bio-Tech Animal Feed Volume Increased 25% in Fourth Quarter of 2007
4. Kiwa Bio-Tech Products Group Holds Meetings to Build Distribution Network
5. Kiwa Bio-Tech Products Group Holds a Fertilizer Products Exhibition in Hebei
6. Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million
7. Align Technology, Inc. Ranked 23rd in Deloittes Technology Fast 50 Program for Silicon Valley Scientific & Medical Equipment, and Bio-Technology Companies
8. Kiwa Bio-Tech Ships 2,700 Tons of Bio-feed in One Month
9. Advanced Bio-Technologies Inc Announces Acquisition by HealthEdge Investment Partners, Tampa FL
10. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
11. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on December 29, 2015 at 11:00 a.m. Israel ... Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... of Eric Paneth and Izhak Tamir to the ... Rami Skaliter as external directors; , approval of an amendment to ...
Breaking Biology Technology:
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... YORK , Nov. 10, 2015 ... to behavioral biometrics that helps to identify and ... fraud. Signature is considered as the secure and ... the identification of a particular individual because each ... more accurate results especially when dynamic signature of ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
Breaking Biology News(10 mins):